文献速递儿童心血管与肾脏儿童神经与发育行为儿童内分泌与遗传代谢

线粒体病患儿心脏移植的结局与并发症比较

Heart Transplantation in Children with Mitochondrial Disease.
PubMed 文献 · J Pediatr · 2019-11-08

该研究基于儿科健康信息系统与移植受者科学登记数据库的链接数据,纳入2002至2016年因心肌病接受心脏移植的1330例患儿,其中47例(3.5%)合并线粒体病。结果显示两组移植后生存率相似,但线粒体病组卒中、机械通气时间、ICU停留时间及再入院住院时长均更高。

要点

  • 线粒体病患儿心脏移植后生存率与无线粒体病患儿相似。
  • 线粒体病组移植后卒中风险更高(11% vs 3%)。
  • 线粒体病组机械通气及ICU停留时间更长,再入院住院时间更长。

核心结论

  • 线粒体病患儿可成功接受心脏移植,生存率与无线粒体病患儿相当。
  • 线粒体病患儿移植后并发症风险更高,包括卒中、机械通气延长、ICU及再入院住院时间延长。
  • 在合适临床情境下,线粒体病不应视为心脏移植的绝对禁忌证。

研究设计与样本

  • 利用儿科健康信息系统与移植受者科学登记数据库的独特链接进行回顾性队列研究。
  • 纳入2002至2016年因心肌病接受心脏移植的儿科受者,共1330例,其中47例(3.5%)合并线粒体病。
  • 比较合并与不合并线粒体病患者的移植后生存率及并发症。

主要发现

  • 中位随访4年期间,合并与不合并线粒体病患者的移植后生存率相似。
  • 线粒体病组移植后卒中发生率11%,无线粒体病组3%(P = .009)。
  • 线粒体病组移植后机械通气时间中位3天,无线粒体病组1天(P < .001)。
  • 线粒体病组移植后ICU停留时间中位10天,无线粒体病组6天(P = .007)。
  • 移植后第一年无再入院比例两组相似(61.7% vs 51%;P = .14),但再入院者中线粒体病组住院时间中位14天,无线粒体病组8天(P = .03)。

临床怎么用

  • 对合并线粒体病的心肌病患儿,心脏移植可作为合适临床情境下的治疗选择,不应绝对禁忌。
  • 移植后需加强监测卒中、呼吸支持需求及ICU停留时间延长的风险。
  • 再入院时应关注线粒体病患儿可能需更长住院时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the outcomes and comorbidities of children with mitochondrial disease undergoing heart transplantation with children without mitochondrial disease. STUDY DESIGN: Using a unique linkage between the Pediatric Health Information System and Scientific Registry of Transplant Recipients databases, pediatric heart transplantation recipients from 2002 to 2016 with a diagnosis of cardiomyopathy were included. Post heart transplantation survival and morbidities were compared between patients with and without mitochondrial disease. RESULTS: A total of 1330 patients were included, including 47 (3.5%) with mitochondrial disease. Survival after heart transplantation was similar between patients with and without mitochondrial disease over a median follow-up of 4 years. Patients with mitochondrial disease were more likely to have a stroke after heart transplantation (11% vs 3%; P = .009), require a longer duration of mechanical ventilation after heart transplantation (3 days vs 1 day; P < .001), and have a longer intensive care unit stay after heart transplantation (10 vs 6 days; P = .007). The absence of a hospital readmission within the first post-transplant year was similar among patients with and without mitochondrial disease (61.7% vs 51%; P = .14). However, patients with mitochondrial disease who were readmitted demonstrated a longer length of stay compared with those without (median, 14 days vs 8 days; P = .03). CONCLUSIONS: Patients with mitochondrial disease can successfully undergo heart transplantation with survival comparable with patients without mitochondrial disease. Patients with mitochondrial disease have greater risk for post-heart transplantation morbidities including stroke, prolonged mechanical ventilation, and longer intensive care unit and readmission length of stay. These results suggest that the presence of mitochondrial disease should not be an absolute contraindication to heart transplantation in the appropriate clinical setting.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Weiner JG, Lambert AN, Thurm C, et al. Heart Transplantation in Children with Mitochondrial Disease. J Pediatr. 2019. PMID: 31711761. doi:10.1016/j.jpeds.2019.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。